For the quarter ending 2026-03-31, ADIL had -$2,152,881 decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Loss from operations | 3,958,616 | -1,793,651 | -4,187,357 |
| Equity-based compensation | -360,264 | 147,334 | 360,830 |
| Amortization of intangible assets | -282 | 141 | 282 |
| Inducement expense | - | - | 0 |
| Change in value of equity method investment | 270,770 | -76,920 | -261,820 |
| Prepaid research and development | - | - | 0 |
| Change in fair value contingent consideration | - | 0 | 150,000 |
| Prepaid expenses and other current assets | -180,122 | 243,896 | -144,592 |
| Accrued expenses, related party | - | - | 0 |
| Accounts payable, related party | - | 0 | 48,272 |
| Accrued expenses | 237,736 | 94,613 | -137,547 |
| Accounts payable | -387,794 | -114,834 | 420,988 |
| Net cash used in operating activities | 3,555,636 | -1,833,373 | -3,334,664 |
| Cash receipt from contingent consideration | - | 0 | -150,000 |
| Net cash provided by investing activities | - | 0 | 150,000 |
| Proceeds from warrant exercise, net of expenses | - | 47,040 | 2,221,932 |
| Net proceeds from sale of common stock | -3,289,545 | 477,642 | 3,127,187 |
| Net cash provided by financing activities | -5,558,517 | 524,682 | 5,349,119 |
| Net (decrease) in cash and cash equivalents | -2,152,881 | -1,308,691 | 2,164,455 |
| Cash and cash equivalents-beginning of period | 1,274,928 | 3,750,525 | - |
| Cash and cash equivalents-end of period | -22,189 | 4,606,289 | - |
ADIAL PHARMACEUTICALS, INC. (ADIL)
ADIAL PHARMACEUTICALS, INC. (ADIL)